Ghana Med J. 2012 Jun;46(2 Suppl):69-78.
Countdown to zero
2011- 2015
Vision 2030
Accessed: 17.11.2019
PeerJ PrePrints , http://dx.doi.org/10.7287/peerj.preprints.579v1 2 Nov 2014
The Community Action Research on Disability (CARD) programme in Uganda embraced and modified the EDR approach, recognising the need for including people with disability in the research process from concept to outcome, and nurturing participation and
...
collaboration between all the stakeholders in achieving action-based research. T
more
• Clashes continued between the Syrian Democratic Forces (SDF), the Syrian Arab Army (SAA), and Turkish backed forces, concentrated around the M4 highway and Tal Tamer district in Al-Hasakeh. Further displacement was reported.
• Several civilian casualties occurred due to improvised explosive
...
devices (IEDs) in Afrin, Quamishli, and along the Tell Abiad-Ras al-Ain corridor. On 16 November, a car bomb in Al Bab, Aleppo reportedly killed 14 people and injured 27, including civilians.
• On 13 November, Alouk water station was repaired following reconnection of the Debarseyah supply line, again restoring water to 460,000 people in Al-Hasakeh city and surrounding areas
more
While the COVID-19 pandemic threatens all members of society, persons with disabilities are disproportionately impacted due to attitudinal, environmental and institutional barriers that are reproduced in the COVID-19 response.
PLOS ONE | https://doi.org/10.1371/journal.pone.0210937
February 5, 2019
Lancet Oncol 2018 Published Online September 12, 2018 http://dx.doi.org/10.1016/S1470-2045(18)30447-9
This was a Phase 3, multi-center, randomized, open-label, parallel-group, active control study where 273 male and female patients with first stage Trypanosoma brucei gambiense HAT were treated at six sites: one trypanosomiasis reference center in Angola, one hospital in South Sudan, and four hospita
...
ls in the Democratic Republic of the Congo between August 2005 and September 2009 to support the registration of pafuramidine for treatment of first stage HAT in collaboration with the United States Food and Drug Administration. Patients were treated with either 100 mg of pafuramidine orally twice a day for 10 days or 4 mg/kg pentamidine intramuscularly once daily for 7 days to assess the efficacy and safety of pafuramidine versus pentamidine. Pregnant and lactating women as well as adolescents were included.
more